Integral Molecular to Present Claudin 6 MAbs, a Therapeutic Asset for Solid Tumors, at Annual AACR Conference
PHILADELPHIA, March 26, 2019 /PRNewswire/ -- Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, will showcase updated data on its discovery of highly specific Claudin 6 MAbs at the 2019 American Association for Cancer Research (AACR) conference in Atlanta on Monday, April 1. Claudin 6 is an established membrane protein target expressed in multiple cancers, including ovarian and gastric tumors, and absent from healthy adult tissues. Until now, the structural complexity of Claudin 6 and its similarity to proteins expressed on healthy tissue have limited its exploitation for targeted oncology therapies.
"There is a strong need for therapeutic monoclonal antibodies that can provide more specific and less toxic treatments for ovarian cancer," said Ross Chambers, VP of Antibody Discovery. "Our lead antibody, isolated using our MPS Antibody Discovery platform, shows best-in-class Claudin 6 specificity. We are currently looking for partners to further develop these exciting assets."
Integral Molecular's MPS Antibody Discovery platform encompasses a comprehensive technology suite that overcomes the obstacles of working with highly conserved and structurally complex membrane protein targets, like Claudin 6. This suite includes antigen engineering and presentation on Lipoparticles, immunization of divergent species, and the use of B-cell cloning to recover rare antibodies. Integral Molecular is currently isolating MAbs against dozens of membrane protein targets and welcomes antibody licensing opportunities and discovery partnerships.
About Integral Molecular
Integral Molecular (www.integralmolecular.com) is the industry leader in discovering antibodies against multipass membrane proteins, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company's extensive experience optimizing membrane proteins, Integral Molecular's technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases.
Contact:
Integral Molecular, Inc.
Ross Chambers, PhD, VP of Antibody Discovery
215-966-6061
[email protected]
www.integralmolecular.com
SOURCE Integral Molecular Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article